Skip to main content

ORIGINAL RESEARCH article

Front. Antibiot.
Sec. Pharmacology
Volume 3 - 2024 | doi: 10.3389/frabi.2024.1395425

Unguarded Liabilities: Borrelia burgdorferi's complex amino acid dependence presents a unique target for inhibition Provisionally Accepted

  • 1Purdue University, United States
  • 2Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases (NIH), United States

The final, formatted version of the article will be published soon.

Receive an email when it is updated
You just subscribed to receive the final version of the article

Recent reports from the CDC approximate 500,000 cases of Lyme disease in the United States yearly, a significant economic burden on the healthcare system. Standard treatment for Lyme disease includes broad spectrum antibiotics, which may be administered for extensive periods of time and result in significant impacts to the patient. Recently, we demonstrated that Borrelia burgdorferi, the causative agent of Lyme disease, is uniquely dependent upon peptide acquisition via an oligopeptide transport (Opp) system. This dependence appears unique to the spirochete; thus, the Opp system may constitute a novel and specific target for inhibition of B. burgdorferi. For proof of concept, we conducted a pilot screen to determine if the Opp system constitutes a viable inhibitor target. OppA2 was utilized as our target protein, as it is the most prolific peptide binding protein throughout the enzootic cycle. We validated a thermal shift assay (TSA) to detect ligand binding against OppA2 and performed a high throughput screen of 2,240 molecules from a diversity set library. TSA results identified eight compounds (C1-8) demonstrating potential binding to OppA2, and growth assays identified C2 and C7 as inhibitors of B. burgdorferi growth. We confirmed by TSA that these two compounds interact with additional B. burgdorferi OppAs, potentially resulting in a cumulative inhibitory effect. Additionally, we showed that these compounds have no effect on Escherichia coli, a bacterium that encodes a dispensable Opp system which serves only as an ancillary nutrient transporter. These data demonstrate that the Opp system of B. burgdorferi acts as a viable drug target, with the potential for targeting multiple OppAs with a single compound. Moreover, the lack of inhibition against E. coli suggests that selective targeting of B. burgdorferi via the Opp system may be possible.

Keywords: Borrelia burgdorferi, Lyme Disease, Spirochete, Oligopeptide, antibiotic

Received: 03 Mar 2024; Accepted: 18 Apr 2024.

Copyright: © 2024 Holly, Kataria, Flaherty and Groshong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Mx. Daniel P. Flaherty, Purdue University, West Lafayette, 47907, Indiana, United States
Mx. Ashley Groshong, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases (NIH), Hamilton, 59840, Maryland, United States